If you have major depressive disorder (MDD), you may be taking an antidepressant. Combination drug therapy is a type of treatment that many doctors and psychiatrists have been increasingly using ...

Schizophrenia, which affects about 1% of Americans, impacts how a person thinks, feels and behaves. doidam10 - stock.adobe.com People who land in the ER for psychedelic use are at significantly ...

If you’re one of the 85% of American adults who drink alcohol, whether occasionally or regularly, it’s important to know that it can interact with any medications you take. If you take several ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial ...

According to GlobalData’s expiry model, KarXT is forecast to reach an annual total of $2.81bn in the US by 2033. Karuna’s New Drug Application (NDA) for KarXT for the treatment of schizophrenia in ...

It is important to follow up with tests if asked by your healthcare provider, as levels of the drug may need to be monitored. Antipsychotics are generally used to treat schizophrenia, but some are ...

Nov 11 (Reuters) - AbbVie (ABBV.N), opens new tab shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening ...

The disappointing AbbVie’s trial results is a benefit for Bristol Myers Squibb & Co’s BMY approved schizophrenia drug, Cobenfy, but they raise questions about using selective muscarinic ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two mid-stage studies. Truist says that Abbvie’s “pain” is ...

The drug candidate at the center of AbbVie’s ... The concept of using M4-selective positive allosteric modulators to treat schizophrenia looked de-risked by the time AbbVie made its play for ...

AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares down more than 10% ...